[go: up one dir, main page]

BR9813124A - Compostos indol 2,3-substituìdos como inibidores cox-2 - Google Patents

Compostos indol 2,3-substituìdos como inibidores cox-2

Info

Publication number
BR9813124A
BR9813124A BR9813124-9A BR9813124A BR9813124A BR 9813124 A BR9813124 A BR 9813124A BR 9813124 A BR9813124 A BR 9813124A BR 9813124 A BR9813124 A BR 9813124A
Authority
BR
Brazil
Prior art keywords
halo
alkoxy
alkyl
substituted
cox
Prior art date
Application number
BR9813124-9A
Other languages
English (en)
Inventor
Kazunari Nakao
Rodney William Stevens
Kiyoshi Kawamura
Chikara Uchida
Hiroki Koike
Stephane Caron
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9813124A publication Critical patent/BR9813124A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS INDOL 2,3-SUBSTITUìDOS COMO INIBIDORES COX-2"<D>. Este invenção proporciona um composto da fórmula seguinte: e os seus sais farmaceuticamente aceitáveis, em que <B>Z<D> representa OH, alcóxi C~ 1-6~, -NR²R³ ou heterociclo; <B>Q<D> é selecionado a partir dos seguintes: (a) fenila facultativamente substituída, (b) um grupo aromático monocíclico de 6 membros contendo um, dois, três ou quatro átomo(s) de nitrogênio, (c) um grupo aromático monocíclico de 5 membros contendo um heteroátomo selecionado a partir de O, S e N, e contendo, facultativamente, um, dois ou três átomo(s) de nitrogênio para além do referido heteroátomo, (d) uma cicloalquila C~ 3-7~ facultativamente substituída e (e) um heterociclo benzo-condensado facultativamente substituída; <B>R¹<D> representa hidrogênio, alquila C~ 1-4~ ou halo; <B>R² e R³<D> representam, independentemente H, OH, alcóxi C~ 1-4~ ou alquila C~ 1-4~ substituído com halo, OH, alcóxi C~ 1-4~, NH~ 2~ ou CN; <B>X<D> é selecionado, independentemente, a partir de halo, alquila C~ 1-4~, alquila C~ 1-4~ substituída com halo, OH, alcóxi C~ 1-4~, alcóxi C~ 1-4~ substituída com halo, alquiltio C~ 1-4~, NO~ 2~, NH~ 2~, di-(alquil C~ 1-4~)-amino e CN; e <B>n<D> representa 0, 1, 2, 3 ou 4. Esta invenção proporciona também uma composição farmacêutica, útil para o tratamento de um estado clínico em que se encontram implicadas, como patogênios, as prostaglandinas.
BR9813124-9A 1998-01-05 1998-12-18 Compostos indol 2,3-substituìdos como inibidores cox-2 BR9813124A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9800003 1998-01-05
PCT/IB1998/002065 WO1999035130A1 (en) 1998-01-05 1998-12-18 2,3-substituted indole compounds as cox-2 inhibitors

Publications (1)

Publication Number Publication Date
BR9813124A true BR9813124A (pt) 2000-10-10

Family

ID=11004645

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813124-9A BR9813124A (pt) 1998-01-05 1998-12-18 Compostos indol 2,3-substituìdos como inibidores cox-2

Country Status (39)

Country Link
US (1) US6608070B1 (pt)
EP (1) EP1045833B1 (pt)
JP (1) JP3347136B2 (pt)
KR (1) KR100404054B1 (pt)
CN (1) CN1284064A (pt)
AP (1) AP869A (pt)
AR (1) AR016977A1 (pt)
AT (1) ATE308519T1 (pt)
AU (1) AU748107B2 (pt)
BG (1) BG104643A (pt)
BR (1) BR9813124A (pt)
CA (1) CA2316863A1 (pt)
CO (1) CO4970807A1 (pt)
DE (1) DE69832200T2 (pt)
DZ (1) DZ2700A1 (pt)
EA (1) EA200000614A1 (pt)
ES (1) ES2255190T3 (pt)
GT (1) GT199800205A (pt)
HN (1) HN1997000098A (pt)
HR (1) HRP20000454A2 (pt)
HU (1) HUP0102922A3 (pt)
ID (1) ID24876A (pt)
IL (1) IL136885A0 (pt)
IS (1) IS5532A (pt)
MA (1) MA24736A1 (pt)
NO (1) NO20003451L (pt)
OA (1) OA11441A (pt)
PA (1) PA8466201A1 (pt)
PE (1) PE20000055A1 (pt)
PL (1) PL341696A1 (pt)
SA (1) SA99191299A (pt)
SK (1) SK9912000A3 (pt)
TN (1) TNSN99001A1 (pt)
TR (1) TR200001906T2 (pt)
TW (1) TW436482B (pt)
UY (2) UY25332A1 (pt)
WO (1) WO1999035130A1 (pt)
YU (1) YU41600A (pt)
ZA (1) ZA9911B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
MXPA00006605A (es) * 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
PT1065206E (pt) * 1999-07-02 2003-01-31 Pfizer Compostos de tetrazolilalquilindole e como agentes anti-inflamatorios e analgesicos
PT1175214E (pt) 1999-12-08 2005-04-29 Pharmacia Corp Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico
EP1572678A4 (en) * 2002-12-19 2008-05-07 Elan Pharm Inc SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
DE602004002832T2 (de) 2003-05-07 2007-06-06 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
KR100795462B1 (ko) * 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
EP2114895A4 (en) 2006-10-17 2011-06-22 Stiefel Laboratories TALARAZOLMETABOLITEN
US20120022121A1 (en) * 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
EP2560956B1 (en) * 2010-04-19 2016-10-26 Octeta Therapeutics, LLC Novel synthesis for thiazolidinedione compounds
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5823514B2 (ja) 2010-07-07 2015-11-25 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2590510B1 (en) * 2010-07-07 2016-09-28 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
RU2593370C2 (ru) 2010-08-10 2016-08-10 Октета Терапьютикс, ЭлЭлСи Новый способ синтеза соединений тиазолидиндиона
CA2807815C (en) 2010-08-10 2018-10-02 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
WO2013138600A1 (en) * 2012-03-16 2013-09-19 Rosen Eliot M Radioprotector compounds
US9808443B1 (en) 2016-11-28 2017-11-07 King Saud University Cyclooxygenase inhibitors
CN111004121A (zh) * 2019-12-09 2020-04-14 南京杰运医药科技有限公司 一种4-烷氧基乙酰乙酸酯类化合物的制备方法
CN112409281B (zh) * 2020-08-20 2022-11-18 上海大学 (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
WO2022260494A1 (ko) * 2021-06-10 2022-12-15 연세대학교 산학협력단 펜드린 억제 활성을 갖는 신규 화합물 및 이의 의약 용도
CN116262721A (zh) * 2023-01-12 2023-06-16 浙江师范大学 一种二氢吲哚衍生物及吲哚衍生物的制备方法及产品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2

Also Published As

Publication number Publication date
SA99191299A (ar) 2005-12-03
PL341696A1 (en) 2001-04-23
ES2255190T3 (es) 2006-06-16
OA11441A (en) 2004-04-27
JP2002500217A (ja) 2002-01-08
TNSN99001A1 (fr) 2005-11-10
EP1045833A1 (en) 2000-10-25
DE69832200T2 (de) 2006-04-20
CA2316863A1 (en) 1999-07-15
DZ2700A1 (fr) 2003-09-01
HUP0102922A2 (hu) 2001-12-28
YU41600A (sh) 2003-08-29
DE69832200D1 (de) 2005-12-08
IL136885A0 (en) 2001-06-14
AR016977A1 (es) 2001-08-01
TW436482B (en) 2001-05-28
AU1500599A (en) 1999-07-26
JP3347136B2 (ja) 2002-11-20
PE20000055A1 (es) 2000-02-08
WO1999035130A1 (en) 1999-07-15
US6608070B1 (en) 2003-08-19
AP869A (en) 2000-09-04
ID24876A (id) 2000-08-31
KR100404054B1 (ko) 2003-11-01
UY25332A1 (es) 2001-01-31
AU748107B2 (en) 2002-05-30
HRP20000454A2 (en) 2001-04-30
HUP0102922A3 (en) 2003-06-30
PA8466201A1 (es) 2000-09-29
EA200000614A1 (ru) 2001-02-26
IS5532A (is) 2000-06-13
AP9801423A0 (en) 1998-12-31
HN1997000098A (es) 1998-12-28
ATE308519T1 (de) 2005-11-15
ZA9911B (en) 2000-07-04
CN1284064A (zh) 2001-02-14
BG104643A (bg) 2001-02-28
UY25590A1 (es) 1999-09-27
NO20003451L (no) 2000-09-01
EP1045833B1 (en) 2005-11-02
KR20010033859A (ko) 2001-04-25
TR200001906T2 (tr) 2001-01-22
MA24736A1 (fr) 1999-10-01
GT199800205A (es) 2000-06-21
SK9912000A3 (en) 2001-11-06
NO20003451D0 (no) 2000-07-04
CO4970807A1 (es) 2000-11-07

Similar Documents

Publication Publication Date Title
BR9813124A (pt) Compostos indol 2,3-substituìdos como inibidores cox-2
TR200400342T4 (tr) Farnezil protein transferazı önlemek için kinolin türevleri.
AR050045A1 (es) Derivados de pirrolo[3,4-c]pirazol activos como inhibidores de quinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
BR9910119A (pt) Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina
BR9807132A (pt) Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2
NO308736B1 (no) 1,2-difenylpyrrolderivater, farmasøytiske preparater inneholdende disse, og deres anvendelse
BR0010520A (pt) Novos compostos farmaceuticamente ativos
PA8548001A1 (es) Derivados aromaticos de acidos dicarboxilicos
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
EE200100558A (et) Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
ATE309194T1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
BR9808843A (pt) Derivados de quinolinona 1,8-anelados inibidores da farnesil transferase substituìdos com imidazóis ligados em n ou em c
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
BR0210504A (pt) Derivados de naftil-indol substituidos, atuantes como inibidores do inibidor tipo 1 (pai-1) do ativador de plasminogênio
BR9915011A (pt) Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
BR9811521A (pt) Composição para tratar ou impedir a glomerulopatia
BRPI0409255A (pt) derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda)
BRPI0416450A (pt) derivados de ácido fosfìnico, inibidores de beta - secretase para o tratamento de mal de alzheimer
BR0309188A (pt) Compostos pirazolo como agentes antiinflamatórios e analgésicos
BR0015195A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas
BR9912612A (pt) Composto de maleimida dissubstituìdo e seu usofarmacêutico
BR9913183A (pt) Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1945 DE 15 - 04 - 2008.